HYDROCHLOROTHIAZIDE TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

HYDROCHLOROTHIAZIDE

Disponible desde:

PRO DOC LIMITEE

Código ATC:

C03AA03

Designación común internacional (DCI):

HYDROCHLOROTHIAZIDE

Dosis:

50MG

formulario farmacéutico:

TABLET

Composición:

HYDROCHLOROTHIAZIDE 50MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

THIAZIDE DIURETICS

Resumen del producto:

Active ingredient group (AIG) number: 0101048001; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2019-04-01

Ficha técnica

HYDROCHLOROTHIAZIDE Product Monograph Page 1 of 23
PRODUCT MONOGRAPH
PR
HYDROCHLOROTHIAZIDE
Hydrochlorothiazide Tablets USP
25 mg and 50 mg
DIURETIC - ANTIHYPERTENSIVE
Pro Doc Ltée
2925 Boul Industriel
Laval, Quebec
H7L 3W9
www.prodoc.qc.ca
Submission Control No: 263745
Date of Revision:
May 24, 2022
HYDROCHLOROTHIAZIDE Product Monograph Page 1 of 23
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
2
SUMMARY
PRODUCT
INFORMATION
..............................................................................................
2
INDICATIONS
AND
CLINICAL
USE
....................................................................................................
2
CONTRAINDICATIONS
.........................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
........................................................................................................
3
ADVERSE
REACTIONS
.........................................................................................................................
7
DRUG
INTERACTIONS
..........................................................................................................................
7
DOSAGE
AND
ADMINISTRATION
....................................................................................................
11
OVERDOSAGE
......................................................................................................................................
12
ACTION
AND
CLINICAL
PHARMACOLOGY
..................................................................................
12
STORAGE
AND
STABILITY
................................................................................................................
13
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING
....................................................................
13
PART II: SCIENTIFIC INFORMATION
..................................................................